Intraday Alerts

Intercept Pharmaceuticals Inc. (ICPT) Has Fallen To A 10-Month Low

By RTTNews Staff Writer ✉ | Published: 11/12/2014 10:22 AM ET |

Intercept Pharmaceuticals Inc. (ICPT) has been declining since the open of trade Tuesday and is now down 12.38 at $160.75.

Intercept Pharmaceuticals has been losing ground for the past week and has dropped to a 10-month low this morning.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.

Biotech Stocks Facing FDA Decision In April 2024

Biotech Stocks Facing FDA Decision in March 2024

Biotech Stocks Facing FDA Decision In November 2023

Latest News Videos

Biotechnology Weekly Update - April 24, 2024

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos

Latest Updates on COVID-19

WHO Defines Uniform Terminology For Air-transmitted Pathogens

Scientists Develop Universal Vaccine That May Protect Humans Against Any Virus

Specific Human Nasal Epithelial Cells Protect Children Against COVID: Study

CDC Study Finds Cardiac Deaths Among Young People Not Connected With Covid Vaccines

COVID-19 Fraud Enforcement Task Force Releases 2024 Report

COVID-19: Drugs in Development

Follow RTT

Editor's Pick
Most Read
Most Emailed

Boston Scientific Boosts FY24 Outlook - Update

Roche Q1 Sales Down, Confirms FY24 View; Stock Down

Dr. Reddy's Recalls Sapropterin Dihydrochloride Powder For Oral Solution

Intercept Pharmaceuticals Inc. (ICPT) Has Fallen To A 10-Month Low

Boston Scientific Boosts FY24 Outlook - Update

Roche Q1 Sales Down, Confirms FY24 View; Stock Down

Dr. Reddy's Recalls Sapropterin Dihydrochloride Powder For Oral Solution

Philip Morris Q1 Results Top Estimates, But Trims FY24 Outlook

Novartis Q1 Profit Tops Market, Lifts FY24 View, Proposes New Chair; Stock Up

Primal Kitchen Avocado Oil Recalled For Packaging Issue

Tesla Slashes Car Prices In China After US Cuts

Infinite Herbs Recalls Select Fresh Organic Basil

FSIS Alerts Against Ground Beef Products For E. Coli Concern

American Express Q3 Results Top Estimates; Reaffirms Outlook

Netflix To Stop Sharing Subscriber Data; Stock Dips

Apple Pulls Out Meta's WhatsApp, Threads From App Store In China

American Express Q3 Results Top Estimates; Reaffirms Outlook

Netflix To Stop Sharing Subscriber Data; Stock Dips

Vertiv Holdings Lifts Annual Outlook - Update

BioArctic And Eisai Collaborate On Evaluating BAN2802 For Alzheimer's Disease

JTC Acquires JPMorgan's First Republic Trust Company Of Delaware For $21 Mln

Schneider Electric Confirms Talks With Bentley Systems On Potential Deal; Stock Down

Pfizer's Emblaveo Gets EU Marketing Authorization For Serious Infectious Disease

Roche Announces FDA Approval For Alecensa

Texas Instruments Inc. Reveals Decline In Q1 Profit, but beats estimates

Tritium DCFC Plunges In Pre-market After Disclosure Of Insolvency

NextEra Energy Reaffirms FY24, FY25, FY26 Adj. EPS Outlook - Update

Incyte To Buy Privately Held Escient Pharma

JetBlue Airways Corp. Q1 Loss Increases, but beats estimates

FTC Sues To Block Tapestry's $8.5 Bln Acquisition Of Capri

PulteGroup, Inc. Q1 Profit Rises, Beats estimates

United Micro Electronics Corp. Q1 Profit Drops

NextEra Energy Partners LP Q1 Earnings Summary

Schneider Electric Confirms Talks With Bentley Systems On Potential Deal; Stock Down

Vattenfall And BASF Sign Purchase Agreement For 49% Of Germany's Nordlicht Offshore Wind Farms

EastGroup Properties Inc. Bottom Line Advances In Q1

LKQ Corp Q1 Profit Down, Misses Estimates; Cuts Guidance - Update

Biogen Q1 Adj. EPS Tops Estimates, But Sales Miss; Reaffirms FY24 Outlook

Munich Re Says Q1 Prel. Profit Above Analysts' View

Verizon Communications Q1 Profit Decreases, but beats estimates